Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
The following section summarizes insights on EZZ Life Science Holdings Ltd's Net Income to Common Excl Extra Items:
We've identified the following companies as similar to EZZ Life Science Holdings Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | Net Income to Common Excl Extra Items |
|---|---|---|
| Vitrafy Life Sciences Ltd | ASX:VFY | -36.062 M |
| Trajan Group Holdings Ltd | ASX:TRJ | -28.481 M |
| Oncosil Medical Ltd | ASX:OSL | -12.604 M |
| Genetic Technologies Ltd | ASX:GTG | -12.017 M |
| Proteomics International Laboratories Ltd | ASX:PIQ | -7.11 M |
| Memphasys Ltd | ASX:MEM | -5.106 M |
| Healthcare | SECTOR:HLTH.AU | -2.973 M |
| Cryosite Ltd | ASX:CTE | 1.832 M |
| EZZ Life Science Holdings Ltd | ASX:EZZ | 9.02 M |
| BioLASCO Taiwan Co Ltd | TPEX:6662 | 42.504 M |
| SCHOTT Pharma AG & Co. KGaA | DB:1SXP | 134.2 M |
| West Pharmaceutical Services Inc | NYSE:WST | 492.7 M |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Net Income to Common Excl Extra Items in the popular category include:
Represents the net income or loss available to common stockholders and is arrived after adjusting preferred stock dividends and other adjustments to n...
EZZ Life Science reported net income to common excl extra items of 9.02 M for the latest twelve months ending December 31, 2024 on its income statement.
The tables below summarizes EZZ Life Science’s Net Income to Common Excl Extra Items and common size over the last five years:
| Fiscal Year | Net Income to Common Excl Extra Items | Revenue | % Revenue |
|---|---|---|---|
| 2020-06-30 | 1.586 M | 17.969 M | 8.8% |
| 2021-06-30 | 2.031 M | 22.287 M | 9.1% |
| 2022-06-30 | 1.312 M | 15.022 M | 8.7% |
| 2023-06-30 | 3.63 M | 37.143 M | 9.8% |
| 2024-06-30 | 6.964 M | 66.443 M | 10.5% |
The tables below summarizes EZZ Life Science’s Net Income to Common Excl Extra Items and common size over the last four quarters:
| Quarter Ending | Net Income to Common Excl Extra Items | Revenue | % Revenue |
|---|---|---|---|
| 2024-03-31 | 2.911 M | 22.373 M | 13.0% |
| 2024-06-30 | 2.911 M | 22.373 M | 13.0% |
| 2024-09-30 | 1.599 M | 15.144 M | 10.6% |
| 2024-12-31 | 1.599 M | 15.144 M | 10.6% |
The chart above depicts the distribution of Net Income to Common Excl Extra Items for companies operating in the Healthcare Sector in the Developed economic region. Over 2,500 companies were considered in this analysis, and 2,405 had meaningful values. The average Net Income to Common Excl Extra Items of companies in the Sector is -1.441 M with a standard deviation of 235.8 M. Please note that Sector and Industry values may differ from other sources, as no adjustments have been made.
EZZ Life Science Holdings Ltd's Net Income to Common Excl Extra Items of 9.02 M ranks in the 81.9% percentile for the Sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,505 |
| Included Constituents | 2,405 |
| Min | -592 M |
| Max | 2.103 B |
| Median | -8.627 M |
| Mean | -1.441 M |
| Standard Deviation | 235.8 M |
You can find companies with similar Net Income to Common Excl Extra Items using this stock screener.